Bayer's Pipeline Momentum Meets a Split Analyst Verdict
Published on 11/18/2026 at 13:20 | Editorial boerse-global.deBayer shares closed Wednesday at EUR 56.02, down 1.4% — a modest pullback that nonetheless leaves the stock sitting neatly between two sharply divergent price targets on the sell side. At the top of that range, Deutsche Bank Research lifted its objective from EUR 60 to EUR 65 on November 10 while reiterating a Buy. At the bottom, Jefferies kept its Hold rating and a EUR 48.50 target the same day. Berenberg, for its part, split the difference in spirit: it raised its target from EUR 53.50 to EUR 62.00 in an analysis published yesterday, yet stayed at Hold. A richer valuation, in other words, has not translated into a chorus of buy calls.
The dispersion reflects genuine uncertainty about what should carry the most weight in the investment case — near-term commercial execution or a longer-dated strategic option. Sebastian Bray, the Berenberg analyst behind the note reported by dpa-AFX, pointed to a possible initial public offering toward the end of the decade, with proceeds potentially channelled into pharmaceutical development. That is a strategic perspective, not a signed transaction, and the distinction matters after a run that has seen the shares gain 54% since the start of the year.
Approvals Give the Pipeline Something Concrete
What investors can already count is a fortnight of regulatory wins. On November 10, the US Food and Drug Administration cleared Asundexian, to be marketed as Sunharbo, for reducing the risk of recurrent strokes in certain adults when used alongside an antiplatelet therapy. Bayer describes it as the first factor XIa inhibitor approved anywhere in the world. Four days earlier, on November 4, China's regulator greenlit Sevabertinib as a first-line treatment for patients with HER2-mutated non-small cell lung cancer, a decision Bayer says rests on the ongoing Phase I/II SOHO-01 trial.
Those clearances landed alongside an upgraded outlook. On November 3, the group raised its guidance for the Pharmaceuticals margin, for group EBITDA before special items and for free cash flow, while simultaneously projecting lower net financial debt. The operating backdrop has thus improved on several fronts at once — a relevant detail when weighing what extra capital from a future listing might actually be worth.
Should investors sell immediately? Or is it worth buying Bayer?
Third-Quarter Numbers Set the Baseline
For the third quarter of 2026, Bayer reported revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Against that base, the case for a Monsanto flotation rests less on the proceeds themselves than on how they would be deployed. Even a completed IPO would first raise capital; whether it creates additional corporate value depends on what is done with the money afterwards. Shareholders therefore need to keep financing and economic success in separate compartments.
The bearish counterpoint is the gap between a strategic idea and a P&L line. Anyone assigning a fixed value contribution to a Monsanto listing today is pre-empting both the transaction and its successful execution. Approvals, similarly, are no substitute for proof of commercial returns. What matters for the next leg of the valuation is whether medical progress shows up in revenue, earnings and cash inflows — and whether the improved operating guidance holds.
Reading Two Signals Together
Berenberg's unchanged Hold recommendation caps the message sent by its higher target. The bank lifted its valuation marker without drawing a more positive investment conclusion from it, and investors would do well to read the two signals as a pair: support for a higher valuation perspective, but no blanket vote of confidence in the long-term transaction idea.
In the favourable scenario, operating improvement continues and a later Monsanto deal could unlock further funds for drug development, making the strategic option more tangible. Should Bayer move the possibility toward concrete steps, the financing benefit could be assessed with greater precision — a potential catalyst, not a guaranteed next move. If operating momentum falters, the long-horizon financing argument loses its pull and cannot automatically offset weaker results. Until confirmation arrives on either front, a possible flotation remains a supplement to the Bayer story rather than its foundation.
Ad
Bayer Stock: New Analysis - 18 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
